| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0272-6386(00)70334-9 |
| P698 | PubMed publication ID | 10676724 |
| P2093 | author name string | Suzuki A | |
| Hori M | |||
| Hayashi T | |||
| Imai E | |||
| Okada N | |||
| Togawa M | |||
| Shoji T | |||
| Tsubakihara Y | |||
| P2860 | cites work | Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study | Q29614968 |
| Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass | Q33641557 | ||
| A simple method of estimating progression of chronic renal failure | Q39413560 | ||
| Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method | Q39802766 | ||
| Trough-to-peak ratio and 24-hour blood pressure control. Methodologic issues | Q40529152 | ||
| Problems in echocardiographic volume determinations: Echocardiographic-angiographic correlations in the presence or absence of asynergy | Q52438719 | ||
| Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients | Q67547801 | ||
| The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease | Q71270716 | ||
| Report on management of renal failure in Europe, XXIV, 1993 | Q71525793 | ||
| Chairman's Workshop Report: Hypertension and cardiovascular effects--long-term safety and potential long-term benefits of r-HuEPO | Q71981012 | ||
| Clinical and echocardiographic disease in patients starting end-stage renal disease therapy | Q72192935 | ||
| Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy | Q72806002 | ||
| Cardiovascular effects of recombinant human erythropoietin in predialysis patients | Q73215887 | ||
| Impact of left ventricular hypertrophy on survival in end-stage renal disease | Q93520188 | ||
| P433 | issue | 2 | |
| P921 | main subject | patient | Q181600 |
| circulatory system | Q11068 | ||
| erythropoietin | Q218706 | ||
| P304 | page(s) | 250-256 | |
| P577 | publication date | 2000-02-01 | |
| P1433 | published in | American Journal of Kidney Diseases | Q4744250 |
| P1476 | title | Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. | |
| P478 | volume | 35 |
| Q38762167 | A Comparative Study of the Hemoglobin-Maintaining Effects Between Epoetin-β Pegol and Darbepoetin-α in Patients with Chronic Kidney Disease During 3 Months Before Dialysis Initiation |
| Q37340514 | A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer |
| Q33639624 | A mild decrease of renal function is related to increased hemoglobin level during 5-year follow-up period |
| Q36001255 | A novel protective effect of erythropoietin in the infarcted heart |
| Q36439698 | Anaemia in diabetes: Is there a rationale to TREAT? |
| Q43633394 | Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study |
| Q46763281 | Anemia among long-term renal transplant recipients. |
| Q36560971 | Anemia and cardiovascular disease in diabetic nephropathy |
| Q35553278 | Anemia as a risk factor for cardiovascular disease |
| Q36689806 | Anemia in diabetes: marker or mediator of microvascular disease? |
| Q35553274 | Anemia of chronic disease: Past, present, and future |
| Q79116622 | Anemia: A Continuing Problem Following Kidney Transplantation |
| Q37930478 | Animal models of cardiorenal syndrome: a review. |
| Q40168645 | Assessment of Anemia and Quality of Life in Patients With Renal Transplantation |
| Q35134442 | Association between the Hemoglobin Level and Cardiothoracic Ratio in Patients on Incident Dialysis. |
| Q36003320 | Association of Estimated Glomerular Filtration Rate with Hemoglobin Level in Korean Adults: The 2010-2012 Korea National Health and Nutrition Examination Survey |
| Q44916343 | Association of anemia with outcomes in men with moderate and severe chronic kidney disease |
| Q31832576 | Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients |
| Q35107195 | Cardiac Performance and Morphology in End-Stage Renal Disease |
| Q35893998 | Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia |
| Q37562631 | Cellular basis of uraemic cardiomyopathy: a role for erythropoietin? |
| Q35117574 | Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes |
| Q44481322 | Chronic renal insufficiency in children: the 2001 Annual Report of the NAPRTCS. |
| Q44908499 | Clinical factors associated with achieving K/DOQI hemoglobin targets in hemodialysis patients |
| Q50925773 | Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity-matched analysis. |
| Q35107199 | Congestive Heart Failure in Patients with Chronic Kidney Disease and on Dialysis |
| Q36253508 | Delivery of predialysis care in an academic referral nephrology practice |
| Q79095503 | Different remodelling against left ventricular overload between diabetic and non‐diabetic haemodialysis patients |
| Q82420698 | Effect of anemia on cardiac disorders in pre-dialysis patients immediately before starting hemodialysis |
| Q36758585 | Emerging drugs for acute and chronic heart failure: current and future developments |
| Q49375907 | Erythropoietin in cardiorenal anemia syndrome |
| Q37152506 | Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q58949564 | Global approach to cardiovascular risk in chronic kidney disease: Reality and opportunities for intervention |
| Q47579873 | Hemoglobin predicts long-term survival in dialysis patients: A 15-year single-center longitudinal study and a correlation trend between prealbumin and hemoglobin |
| Q53814702 | Impact of anaemia treatment for left ventricular remodelling prior to initiation of dialysis in chronic kidney disease patients: Efficacy and stability of long acting erythropoietin stimulating agents. |
| Q37276822 | Impact of epoetin alfa on left ventricular structure, function, and pressure volume relations as assessed by cardiac magnetic resonance: the heart failure preserved ejection fraction (HFPEF) anemia trial |
| Q79360996 | Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin |
| Q79267929 | Left ventricular hypertrophy: a surrogate end point or correlate of cardiovascular events in kidney disease? |
| Q38504920 | Less known pathophysiological mechanisms of anemia in patients with diabetic nephropathy |
| Q62131717 | Long‐term impact of renal transplantation on carotid artery properties and on ventricular hypertrophy in end‐stage renal failure patients |
| Q49027440 | Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients |
| Q47731990 | Morbidity and mortality in children with anemia at initiation of dialysis |
| Q46057626 | Negative effects of anemia on quality of life and its improvement by complete correction of anemia by administration of recombinant human erythropoietin in posttransplant patients |
| Q80335867 | Pilot study of the optimum hematocrit for patients in the predialysis stage after renal transplantation |
| Q46733484 | Positive correlation of CRP and fibrinogen levels as cardiovascular risk factors in early stage of continuous ambulatory peritoneal dialysis patients |
| Q48576546 | Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study |
| Q79104638 | Predialysis Care in Diabetic Patients: The Missing Link? |
| Q28468444 | Predictive Factors of One-Year Mortality in a Cohort of Patients Undergoing Urgent-Start Hemodialysis |
| Q35811858 | Predictors of anemia in a multi-ethnic chronic kidney disease population: a case-control study |
| Q44125448 | Prognostic significance of left ventricular hypertrophy observed at dialysis initiation depends on the pre-dialysis use of erythropoiesis-stimulating agents |
| Q35553269 | Prospective trials on anemia of chronic disease: The Trial to Reduce Cardiovascular Events with Aranesp® Therapy (TREAT) |
| Q36661294 | Recombinant human epoetin beta in the treatment of renal anemia |
| Q36298407 | Report of an NIH task force on research priorities in chronic kidney disease in children |
| Q39720848 | Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients |
| Q34410068 | Short- and long-term effects of erythropoietin treatment on endothelial progenitor cell levels in patients with cardiorenal syndrome |
| Q34549905 | Should hemoglobin be normalized in patients with chronic kidney disease? |
| Q35208122 | The anaemia of silent diabetic nephropathy-prevalence, physiopathology, and management |
| Q36547323 | The epidemics of cardiovascular disease in elderly patients with chronic kidney disease--two facets of the same problem |
| Q34506890 | The role of anaemia in the genesis of cardiac abnormalities in patients with chronic kidney disease |
| Q33646679 | The role of anemia management in improving outcomes for African-Americans with chronic kidney disease |
| Q30442221 | Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy |
| Q35116415 | Treatment of anemia in the diabetic patient with retinopathy and kidney disease |
| Q38859858 | Type 2 Diabetes and Heart Failure: Challenges and Solutions. |
| Q83879593 | [Anemia in chronic kidney disease and its cardiovascular implications] |
Search more.